Merus N.V.: 5%+ holders

As of November 6, 2026, Merus N.V. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 9 filings are on record since August 12, 2025 (Schedule 13G/A, February 17, 2026).

Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies ↓

Sell to companies like Merus N.V? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-02-17 · Holder: Paradigm BioCapital Advisors LP · Percent: 0% · SCHEDULE 13G/A
• Event date 2025-12-30 · Holder: Genmab A/S · Percent: 0% · Shares: 0 · SCHEDULE 13D/A
• Filed 2025-12-19 · Holder: Genmab A/S · Percent: 94.8% · SCHEDULE 13D
• Filed 2025-11-14 · Holder: Paradigm BioCapital Advisors LP · Percent: 6.2% · SCHEDULE 13G/A
• Filed 2025-11-14 · Holder: RTW Investments, LP · Percent: 2.7% · SCHEDULE 13G/A

Merus N.V. has 9 Schedule 13D or 13G filings on record since 2025-08-12. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Merus N.V. and the warning signs.

See Merus N.V.'s free Snapshot Watch Merus N.V.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Merus N.V. and the records around it.

Companies that share a holder

• Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
• Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
• RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)

Want the whole picture on Merus N.V.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Merus N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Merus N.V. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

Genmab A/S

Item 4 of the Schedule 13D is amended and restated in its entirety as follows: "The purpose of the transactions described in this Schedule 13D is for the Reporting Persons to acquire control of all of the issued and outstanding Common Shares of the Issuer while allowing all of the Issuer's shareholders an opportunity to receive the purchase price of $97.00 per Common Share by tendering their Common Shares pursuant to the Offer. At 5:00 p.m. New York City time on December 29, 2025, the Subsequent Offering Period expired. The Common Shares ceased to trade on Nasdaq prior to the opening of trading on December 30, 2025, and Nasdaq has filed with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 to delist the Common Shares from Nasdaq and deregister the Common Shares under Section 12(b) of the Exchange Act. In addition, after the Form 25 becomes effective, Purchaser intends to cause the Issuer to file with the SEC a Certification and Notice of Termination of Registration on Form 15 and take steps to cause the suspension of all of the Issuer's reporting obligations to the SEC with respect to the Common Shares. The information set forth in the section of the Offer to Purchase entitled "Summary Term Sheet" and "Purpose of the Offer; Back-End Transactions; Plans for Merus" is incorporated herein by reference. The foregoing summary is qualified in its entirety by the full text of the Offer to Purchase, which are …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-30; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Merus N.V.. With no account yet, you sign up free and land on the result.

• Get an alert when Merus N.V. is mentioned again
• Find former Merus N.V. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes